144 related articles for article (PubMed ID: 36710485)
1. Prognostic prediction of lung adenocarcinoma by integrative analysis of RHOH expression and methylation.
Kuang M; Zhou Z; Lu Z; Shen W; Ge H; Tao X; Zhao Y; Zhuge L; Sun Y; Ji D; Zhang H
Clin Respir J; 2023 Mar; 17(3):148-156. PubMed ID: 36710485
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
[TBL] [Abstract][Full Text] [Related]
3. Aberrant expression of GSTM5 in lung adenocarcinoma is associated with DNA hypermethylation and poor prognosis.
Hao X; Zhang J; Chen G; Cao W; Chen H; Chen S
BMC Cancer; 2022 Jun; 22(1):685. PubMed ID: 35729618
[TBL] [Abstract][Full Text] [Related]
4. A methylation-based nomogram for predicting survival in patients with lung adenocarcinoma.
Wang X; Zhou B; Xia Y; Zuo J; Liu Y; Bi X; Luo X; Zhang C
BMC Cancer; 2021 Jul; 21(1):801. PubMed ID: 34247575
[TBL] [Abstract][Full Text] [Related]
5. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
Xu XL; Gong Y; Zhao DP
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
[TBL] [Abstract][Full Text] [Related]
6. GALNT2/14 overexpression correlate with prognosis and methylation: potential therapeutic targets for lung adenocarcinoma.
Yu Y; Wang Z; Zheng Q; Li J
Gene; 2021 Jul; 790():145689. PubMed ID: 33964375
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of KIF18A promotes cell proliferation, inhibits apoptosis, and independently predicts unfavorable prognosis in lung adenocarcinoma.
Zhong Y; Jiang L; Lin H; Li X; Long X; Zhou Y; Li B; Li Z
IUBMB Life; 2019 Jul; 71(7):942-955. PubMed ID: 30817091
[TBL] [Abstract][Full Text] [Related]
8. Aberrant S100A16 expression might be an independent prognostic indicator of unfavorable survival in non-small cell lung adenocarcinoma.
Chen D; Luo L; Liang C
PLoS One; 2018; 13(5):e0197402. PubMed ID: 29746588
[TBL] [Abstract][Full Text] [Related]
9. Screening of Methylation Gene Sites as Prognostic Signature in Lung Adenocarcinoma.
Dong M; Yang Z; Li X; Zhang Z; Yin A
Yonsei Med J; 2020 Dec; 61(12):1013-1023. PubMed ID: 33251775
[TBL] [Abstract][Full Text] [Related]
10. Methylation- and homologous recombination deficiency-related mutant genes predict the prognosis of lung adenocarcinoma.
Nie GJ; Liu J; Zou AM; Zhan SF; Liang JK; Sui Y; Chen YN; Yao WS
J Clin Lab Anal; 2022 Apr; 36(4):e24277. PubMed ID: 35238419
[TBL] [Abstract][Full Text] [Related]
11. Elevated Expression of
Hu P; Huang Y; Gao Y; Yan H; Li X; Zhang J; Wang Y; Zhao Y
DNA Cell Biol; 2020 Apr; 39(4):522-532. PubMed ID: 32040344
[TBL] [Abstract][Full Text] [Related]
12. Protein phosphatase 1 regulatory subunit 3G (PPP1R3G) correlates with poor prognosis and immune infiltration in lung adenocarcinoma.
Zhuo X; Chen L; Lai Z; Liu J; Li S; Hu A; Lin Y
Bioengineered; 2021 Dec; 12(1):8336-8346. PubMed ID: 34592886
[TBL] [Abstract][Full Text] [Related]
13. Identification of a methylomics-associated nomogram for predicting overall survival of stage I-II lung adenocarcinoma.
Wang H; Wei C; Pan P; Yuan F; Cheng J
Sci Rep; 2021 May; 11(1):9938. PubMed ID: 33976305
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide analysis of methylation CpG sites in gene promoters identified four pairs of CpGs-mRNAs associated with lung adenocarcinoma prognosis.
Pan X; Ji P; Deng X; Chen L; Wang W; Li Z
Gene; 2022 Feb; 810():146054. PubMed ID: 34737001
[TBL] [Abstract][Full Text] [Related]
15. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
Yang Y; Wang M; Liu B
J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
[TBL] [Abstract][Full Text] [Related]
16. Mining TCGA and GEO databases for the prediction of poor prognosis in lung adenocarcinoma based on up-regulated expression of TNS4.
Liu F; Gao X; Liu W; Xue W
Medicine (Baltimore); 2022 Oct; 101(42):e31120. PubMed ID: 36281194
[TBL] [Abstract][Full Text] [Related]
17.
Zhang W; Li T; Hu B; Li H
Technol Cancer Res Treat; 2020; 19():1533033820957030. PubMed ID: 33084541
[TBL] [Abstract][Full Text] [Related]
18. Immune- and Stemness-Related Genes Revealed by Comprehensive Analysis and Validation for Cancer Immunity and Prognosis and Its Nomogram in Lung Adenocarcinoma.
Chen M; Wang X; Wang W; Gui X; Li Z
Front Immunol; 2022; 13():829057. PubMed ID: 35833114
[TBL] [Abstract][Full Text] [Related]
19. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
20. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
Front Immunol; 2021; 12():724741. PubMed ID: 34335635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]